Kraan Heleen, van Herpen Paul, Kersten Gideon, Amorij Jean-Pierre
Institute of Translational Vaccinology (Intravacc), Antonie van Leeuwenhoeklaan 9, P.O. Box 450, 3720 AL, Bilthoven, The Netherlands.
Pharm Res. 2014 Oct;31(10):2618-29. doi: 10.1007/s11095-014-1359-6. Epub 2014 Apr 24.
The aim of current study was to develop a dried inactivated polio vaccine (IPV) formulation with minimal loss during the drying process and improved stability when compared with the conventional liquid IPV.
Extensive excipient screening was combined with the use of a Design of Experiment (DoE) approach in order to achieve optimal results with high probability.
Although it was shown earlier that the lyophilization of a trivalent IPV while conserving its antigenicity is challenging, we were able to develop a formulation that showed minimal loss of potency during drying and subsequent storage at higher temperatures.
This study showed the potential of a highly stable and safe lyophilized polio vaccine, which might be used in developing countries without the need of a cold-chain.
本研究的目的是开发一种冻干灭活脊髓灰质炎疫苗(IPV)制剂,使其在干燥过程中损失最小,并与传统液体IPV相比具有更好的稳定性。
广泛的辅料筛选与实验设计(DoE)方法相结合,以高概率获得最佳结果。
尽管先前已表明,在保留其三价IPV抗原性的同时进行冻干具有挑战性,但我们能够开发出一种制剂,该制剂在干燥及随后在较高温度下储存期间效力损失最小。
本研究显示了一种高度稳定且安全的冻干脊髓灰质炎疫苗的潜力,这种疫苗可能无需冷链即可在发展中国家使用。